Bone marrow microenvironment and differentiation of leukemia cells

doi:10.3760/cma.j.cn371439-20200619-00038

Abstract

Abstract:

Bone marrow microenvironment (BMM) is the environment on which leukemia cells depend. It contains stem cells, bone marrow stromal cells, and abundant cytokines, which can regulate the differentiation and proliferation of leukemia cells. The regulation of BMM on the differentiation of leukemia cells is a complex process that can act on different targets and signaling pathways. It mainly includes hypoxia-inducible factor, integrins, Notch, and Wnt/β-catenin signal pathways. The study of relationship between BMM and leukemia cell differentiation can help to find pathways and targets that induce leukemia differentiation which will find new directions for the treatment of leukemia.

Key words: Bone marrow, Leukemia, Cell differentiation, Microenvironment

Chen Xi, Mu Dan, Yan Qin, Liu Wenjun. Bone marrow microenvironment and differentiation of leukemia cells[J]. Journal of International Oncology, 2021, 48(3): 189-192.

References 33

[1]	Cheng CW, Yilmaz ÖH. Starving leukemia to induce differentiation[J]. Nat Med, 2017,23(1):14-15. DOI: 10.1038/nm.4259.
[2]	Deynoux M, Sunter N, Hérault O, et al. Hypoxia and hypoxia-inducible factors in leukemia[J]. Front Oncol, 2016,6:41. DOI: 10.3389/fonc.2016.00041. doi: 10.3389/fonc.2016.00041 pmid: 26955619
[3]	Ben El Makki A, Mahtat EM, Kheyi J, et al. A rare case of perimyocarditis induced by all-trans retinoic acid administration during induction treatment of acute promyelocytic leukemia[J]. Med Pharm Rep, 2019,92(4):418-420. DOI: 10.15386/mpr-1229.
[4]	McCulloch D, Brown C, Iland H. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives[J]. Onco Targets Ther, 2017,10:1585-1601. DOI: 10.2147/OTT.S100513. pmid: 28352191
[5]	Cha YJ, Koo JS. Roles of omental and bone marrow adipocytes in tumor biology[J]. Adipocyte, 2019,8(1):304-317. DOI: 10.1080/21623945.2019.1643189.
[6]	Fu JF, Liang ST, Huang YJ, et al. Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model[J]. Int J Cancer, 2017,140(5):1159-1172. DOI: 10.1002/ijc.30515. pmid: 27859216
[7]	Duarte D, Hawkins ED, Lo Celso C. The interplay of leukemia cells and the bone marrow microenvironment[J]. Blood, 2018,131(14):1507-1511. DOI: 10.1182/blood-2017-12-784132. pmid: 29487069
[8]	Seipel K, Schmitter K, Bacher U, et al. Rationale for a combination therapy consisting of MCL1- and MEK-inhibitors in acute myeloid leukemia[J]. Cancers (Basel), 2019,11(11):1779. DOI: 10.3390/cancers11111779.
[9]	Chan SM. The making of a leukemic stem cell: a novel role for IKZF2 in AML stemness and differentiation[J]. Cell Stem Cell, 2019,24(1):5-6. DOI: 10.1016/j.stem.2018.12.007. doi: 10.1016/j.stem.2018.12.007 pmid: 30609399
[10]	Verhagen HJMP, Van Gils N, Martiañez T, et al. IGFBP7 induces differentiation and loss of survival of human acute myeloid leukemia stem cells without affecting normal hematopoiesis[J]. Cell Rep, 2018,25(11):3021-3035. DOI: 10.1016/j.celrep.2018.11.062. doi: 10.1016/j.celrep.2018.11.062 pmid: 30540936
[11]	Sterner RM, Kremer KN, Dudakovic A, et al. Tissue-nonspecific alkaline phosphatase is required for MC3T3 osteoblast-mediated protection of acute myeloid leukemia cells from apoptosis[J]. J Immunol, 2018,201(3):1086-1096. DOI: 10.4049/jimmunol.1800174. pmid: 29914885
[12]	Gibbs BF, Yasinska IM, Oniku AE, et al. Effects of stem cell factor on hypoxia-inducible factor 1 alpha accumulation in human acute myeloid leukaemia and LAD2 mast cells[J]. PLoS One, 2011,6(7):e22502. DOI: 10.1371/journal.pone.0022502.
[13]	Zhe N, Chen S, Zhou Z, et al. HIF-1α inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia[J]. Cancer Biol Ther, 2016,17(6):625-634. DOI: 10.1080/15384047.2016.1177679. pmid: 27082496
[14]	Serra S, Vaisitti T, Audrito V, et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment[J]. Blood Adv, 2016,1(1):47-61. DOI: 10.1182/bloodadvances.2016000984. doi: 10.1182/bloodadvances.2016000984 pmid: 29296695
[15]	Griggio V, Vitale C, Todaro M, et al. HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia[J]. Haematologica, 2020,105(4):1042-1054. DOI: 10.3324/haematol.2019.217430. doi: 10.3324/haematol.2019.217430 pmid: 31289209
[16]	Valsecchi R, Coltella N, Belloni D, et al. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment[J]. Blood, 2016,127(16):1987-1997. DOI: 10.1182/blood-2015-07-657056. doi: 10.1182/blood-2015-07-657056 pmid: 26825709
[17]	Zucchetto A, Tissino E, Chigaev A, et al. Methods for investigating VLA-4 (CD49d/CD29) expression and activation in chronic lymphocytic leukemia and its clinical applications[J]. Methods Mol Biol, 2019,1881:101-112. DOI: 10.1007/978-1-4939-8876-1_8. pmid: 30350200
[18]	Gutjahr JC, Bayer E, Yu XB, et al. CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity[J]. Haematologica, 2020, haematol.2019.231944. DOI: 10.3324/haematol.2019.231944.
[19]	孔庆琳, 安曦洲, 管贤敏, 等. β整合素家族在儿童急性T淋巴细胞白血病的表达及其临床意义[J]. 中国当代儿科杂志, 2017,19(6):620-626. DOI: 10.7499/j.issn.1008-8830.2017.06.003.
[20]	Dal Bo M, Tissino E, Benedetti D, et al. Functional and clinical significance of the integrin alpha chain CD49d expression in chronic lymphocytic leukemia[J]. Curr Cancer Drug Targets, 2016,16(8):659-668. DOI: 10.2174/1568009616666160809102219. pmid: 27514846
[21]	McCarter AC, Wang Q, Chiang M. Notch in leukemia[J]. Adv Exp Med Biol, 2018,1066:355-394. DOI: 10.1007/978-3-319-89512-3_18. pmid: 30030836
[22]	Ciciarello M, Corradi G, Loscocco F, et al. The yin and yang of the bone marrow microenvironment: pros and cons of mesenchymal stromal cells in acute myeloid leukemia[J]. Front Oncol, 2019,9:1135-1143. DOI: 10.3389/fonc.2019.01135. doi: 10.3389/fonc.2019.01135 pmid: 31709192
[23]	Bellavia D, Palermo R, Felli MP, et al. Notch signaling as a therapeutic target for acute lymphoblastic leukemia[J]. Expert Opin on Ther Targets, 2018,22(4):331-342. DOI: 10.1080/14728222.2018.1451840.
[24]	Xiu Y, Dong Q, Fu L, et al. Coactivation of NF-κB and Notch signaling is sufficient to induce B cell transformation and enables B-myeloid conversion[J]. Blood, 2020,135(2):108-120. DOI: 10.1182/blood.2019001438. doi: 10.1182/blood.2019001438 pmid: 31697816
[25]	Takam Kamga P, Bassi G, Cassaro A, et al. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia[J]. Oncotarget, 2016,7(16):21713-21727. DOI: 10.18632/oncotarget.7964. doi: 10.18632/oncotarget.7964 pmid: 26967055
[26]	Bill M, Pathmanathan A, Karunasiri M, et al. EGFL7 antagonizes Notch signaling and represents a novel therapeutic target in acute myeloid leukemia[J]. Clin Cancer Res, 2020,26(3):669-678. DOI: 10.1158/1078-0432.CCR-19-2479. pmid: 31672772
[27]	Mangolini M, Götte F, Moore A, et al. Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia[J]. Nat Commun, 2018,9(1):3839. DOI: 10.1038/s41467-018-06069-5. doi: 10.1038/s41467-018-06069-5 pmid: 30242258
[28]	Wu W, Nie L, Zhang L, et al. The Notch pathway promotes NF-κB activation through Asb2 in T cell acute lymphoblastic leukemia cells[J]. Cell Mol Biol Lett, 2018,23:37. DOI: 10.1186/s11658-018-0102-4. pmid: 30116272
[29]	Almars A, Chondrou PS, Onyido EK, et al. Increased FLYWCH1 expression is negatively correlated with Wnt/β-catenin target gene expression in acute myeloid leukemia cells[J]. Int J Mol Sci, 2019,20(11):2739.
[30]	Zhou H, Mak PY, Mu H, et al. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo[J]. Leukemia, 2017, (10):2065-2074. DOI: 10.1038/leu.2017.87. doi: 10.1038/leu.2017.87 pmid: 28321124
[31]	Huang B, He A, Zhang P, et al. Targeted silencing of genes related to acute monocytic leukaemia by CpG(B)-MLAA-34 siRNA conjugates[J]. J Drug Target, 2020,28(5):516-524. DOI: 10.1080/1061186X.2019.1689397. doi: 10.1080/1061186X.2019.1689397 pmid: 31718329
[32]	Jiang X, Mak PY, Mu H, et al. Disruption of Wnt/β-catenin exerts antileukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia[J]. Clin Cancer Res, 2018,24(10):2417-2429. DOI: 10.1158/1078-0432.CCR-17-1556. doi: 10.1158/1078-0432.CCR-17-1556 pmid: 29463558
[33]	Yang S, Gu Y, Wang G, et al. HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling[J]. Int J Mol Med, 2019,44(2):427-436. DOI: 10.3892/ijmm.2019.4229. doi: 10.3892/ijmm.2019.4229 pmid: 31173171